Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
Untreated Resectable Pancreatic Adenocarcinoma|Borderline Resectable Pancreatic Adenocarcinoma|Locally Advanced Pancreatic Adenocarcinoma
DRUG: Paclitaxel protein bound|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Hydroxychloroquine
Normalization Rate of CA 19-9, Evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy., 6 months
Resectability Rate, Assess the resectability rate following neoadjuvant chemotherapy, 6 months to 2 years|Survival Rate, Assess the 2 year survival from date of study entry, 2 years|Response Rate, Assess the pathologic complete response rate and radiologic response rate, 6 months to 2 years|Incidence of Treatment-Emergent Adverse Events, Assess the Grade 3 or Grade 4 related adverse events as assessed by CTCAE Version 5.0, 6 months to 2 years
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.